|
|
Carmen Urbich, Ziad Mallat, Alain Tedgui, Matthias Clauss, Andreas M. Zeiher, Stefanie Dimmeler
J Clin Invest. 2001;
108(10):1451
doi:10.1172/JCI13620
Abstract |
Full text
| PDF

A
therosclerosis is an inflammatory disease of large arteries that is initiated through the activation of endothelium by proinflammatory mediators. CD40 receptor stimulation has been implicated in the pathogenesis of atherosclerosis. One of the most important atheroprotective stimuli is the viscous drag (shear stress) generated by the streaming blood acting on the endothelial monolayer. Here, we demonstrate that shear stress prevents CD40 ligand–induced endothelial cell activation, and we identify upregulation of TNF receptor–associated factor-3 (TRAF-3) as a potent CD40-inhibitory mechanism. Shear stress specifically upregulates TRAF-3 in cultured endothelial cells. Moreover, in the endothelial cells overlying human atherosclerotic plaques, TRAF-3 expression is upregulated in areas with high shear stress. Overexpression of TRAF-3 inhibits endothelial expression of proinflammatory cytokines and tissue factor and blocks DNA-binding activity of the transcription factor AP-1; it thereby prevents CD40-induced endothelial activation. Thus, upregulation of TRAF-3 represents a novel mechanism for preserving the functional integrity of the endothelial monolayer.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(5)
| Title and authors |
Publication |
Year |
Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile.
Esther Lutgens, Dirk Lievens, Linda Beckers, Erwin Wijnands, Oliver Soehnlein, Alma Zernecke, Tom Seijkens, David Engel, Jack Cleutjens, Anna M Keller, Shalin H Naik, Louis Boon, Hafid Ait Oufella, Ziad Mallat, Cory L Ahonen, Randolph J Noelle, Menno P de Winther, Mat J Daemen, Erik A Biessen, Christian Weber
|
J. Exp. Med.
|
2010 |
Soluble CD40 Ligand as a Predictor of Coronary Artery Disease and Long-Term Clinical Outcomes in Stable Patients Undergoing Coronary Angiography
Matthew T. Rondina, Jason M. Lappé, John F. Carlquist, Joseph B. Muhlestein, Matthew J. Kolek, Benjamin D. Horne, Robert R. Pearson, Jeffrey L. Anderson
|
Cardiology
|
2008 |
Increased soluble CD40L levels are reduced by long-term simvastatin treatment in peritoneally dialyzed patients
Jolanta Malyszko, Jacek S Malyszko, Tomasz Hryszko, Michal Mysliwiec
|
Blood Coagulation & Fibrinolysis
|
2004 |
CD40 and CD40L expression in the chicken embryo aorta: Possible role in the endothelial-mesenchymal transdifferentiation process
Enrique Arciniegas, Aniuska Becerra, Juan B. de Sanctis, Armando Graterol, Richard Ram�rez
|
Anat. Rec.
|
2003 |
Soluble CD40 Ligand in Acute Coronary Syndromes
Christopher Heeschen, Stefanie Dimmeler, Christian W. Hamm, Marcel J. van den Brand, Eric Boersma, Andreas M. Zeiher, Maarten L. Simoons
|
N Engl J Med
|
2003 |
|